Open Access

Dynamic susceptibility contrast‑enhanced perfusion magnetic resonance imaging parameters for predicting MGMT promoter methylation and prognostic value in newly diagnosed patients with glioblastoma 

  • Authors:
    • Daiki Chida
    • Yoshiko Okita
    • Reina Utsugi
    • Hideki Kuroda
    • Ryuichi Hirayama
    • Noriyuki Kijima
    • Atsuko Arisawa
    • Naoki Kagawa
    • Yonehiro Kanemura
    • Shinichi Yoshimura
    • Noriyuki Tomiyama
    • Haruhiko Kishima
  • View Affiliations

  • Published online on: October 14, 2024     https://doi.org/10.3892/ol.2024.14741
  • Article Number: 610
  • Copyright: © Chida et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

 O6‑methylguanine DNA methyltransferase (MGMT) promoter methylation is an important clinical biomarker of newly diagnosed glioblastoma. Previous radiological studies using dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) perfusion have aimed to predict MGMT methylation status non‑invasively in gliomas with radiological characteristics. The possibility of predicting MGMT methylation status using DSC‑MRI perfusion with a radiological approach remains controversial. The present study aimed to evaluate the usefulness of MRI perfusion parameters as non‑invasive markers to predict MGMT methylation status and prognosis in newly diagnosed glioblastoma patients. Thus, 50 patients with histologically confirmed primary glioblastoma, IDH‑wildtype who underwent tumor resection at Osaka University Hospital (Suita, Japan) between January 2017 and January 2023 were included in this study. The mean cerebral blood volume (CBV) ratio (rCBV) and cerebral blood flow (CBF) ratio (rCBF) for tumors with MGMT methylation (mean rCBV:2.09 and mean rCBF:3.08) were significantly higher compared with those for tumors without MGMT methylation (mean rCBV:1.33 and mean rCBF:1.85; P<0.05). While patients with MGMT methylation had longer progression‑free survival (PFS) compared with those without MGMT methylation (P<0.05), there was no significant difference in OS with or without MGMT methylation (P=0.06). By contrast, there was no association between MRI perfusion parameters and OS or PFS in patients with glioblastoma. Furthermore, the association between CBV, CBF, MGMT promotor methylation status, OS, and PFS were explored. There was no significant prognostic difference between low vascularity tumors (rCBV <1.3 or rCBF <1.8) with or without MGMT methylation. On the other hand, high vascularity tumors (rCBF ≥1.8) with MGMT promotor methylation were associated to longer OS and PFS compared with those without. However, there was no association between MGMT methylation status and OS or PFS in patients with high rCBV (rCBV ≥1.3). The present study indicated that CBV and CBF could be used to predict the MGMT methylation status in glioblastomas. However, the prognostic value of tumor vascularity and MGMT methylation status may be limited.
View Figures
View References

Related Articles

Journal Cover

December-2024
Volume 28 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chida D, Okita Y, Utsugi R, Kuroda H, Hirayama R, Kijima N, Arisawa A, Kagawa N, Kanemura Y, Yoshimura S, Yoshimura S, et al: Dynamic susceptibility contrast‑enhanced perfusion magnetic resonance imaging parameters for predicting <em>MGMT</em> promoter methylation and prognostic value in newly diagnosed patients with glioblastoma&nbsp;. Oncol Lett 28: 610, 2024.
APA
Chida, D., Okita, Y., Utsugi, R., Kuroda, H., Hirayama, R., Kijima, N. ... Kishima, H. (2024). Dynamic susceptibility contrast‑enhanced perfusion magnetic resonance imaging parameters for predicting <em>MGMT</em> promoter methylation and prognostic value in newly diagnosed patients with glioblastoma&nbsp;. Oncology Letters, 28, 610. https://doi.org/10.3892/ol.2024.14741
MLA
Chida, D., Okita, Y., Utsugi, R., Kuroda, H., Hirayama, R., Kijima, N., Arisawa, A., Kagawa, N., Kanemura, Y., Yoshimura, S., Tomiyama, N., Kishima, H."Dynamic susceptibility contrast‑enhanced perfusion magnetic resonance imaging parameters for predicting <em>MGMT</em> promoter methylation and prognostic value in newly diagnosed patients with glioblastoma&nbsp;". Oncology Letters 28.6 (2024): 610.
Chicago
Chida, D., Okita, Y., Utsugi, R., Kuroda, H., Hirayama, R., Kijima, N., Arisawa, A., Kagawa, N., Kanemura, Y., Yoshimura, S., Tomiyama, N., Kishima, H."Dynamic susceptibility contrast‑enhanced perfusion magnetic resonance imaging parameters for predicting <em>MGMT</em> promoter methylation and prognostic value in newly diagnosed patients with glioblastoma&nbsp;". Oncology Letters 28, no. 6 (2024): 610. https://doi.org/10.3892/ol.2024.14741